Literature DB >> 19330337

[Diagnostics of glomerulonephritis].

S M Weiner1, R Waldherr, J Kriegsmann.   

Abstract

Glomerulonephritis occurs frequently in patients with multisystemic rheumatic disease, especially in collagen vascular disorders and vasculitides. From a clinical point of view nephrotic syndrome has to be distinguished from nephritic syndrome. Rapid deterioration of renal function is referred to as rapid progressive glomerulonephritis. The differential diagnosis of glomerulonephritis can be narrowed by the findings on urine sediment, amount of proteinuria, degree of renal insufficiency and serological findings. In particular, the presence of urine acanthocytes and cellular casts are diagnostic for glomerulonephritis or vasculitis. Renal biopsy is necessary to establish the final diagnosis in most cases; however, some histological pattern such as membranous glomerulonephritis may occur in several different etiopathogenetic diseases and one disease process may lead to different histomorphologic pictures. Rapid progressive glomerulonephritis is a nephrological emergency and should be diagnosed and treated early to prevent dialysis-dependent renal insufficiency.

Entities:  

Mesh:

Year:  2009        PMID: 19330337     DOI: 10.1007/s00393-008-0399-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  34 in total

Review 1.  Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.

Authors:  Abraham Rutgers; Marjan Slot; Pieter van Paassen; Peter van Breda Vriesman; Peter Heeringa; Jan Willem Cohen Tervaert
Journal:  Am J Kidney Dis       Date:  2005-08       Impact factor: 8.860

2.  Dysmorphic erythrocytes.

Authors:  E Wandel
Journal:  Nephrol Dial Transplant       Date:  1996-09       Impact factor: 5.992

3.  Anticytoplasmic antibodies in Wegener's granulomatosis.

Authors:  F J van der Woude
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

4.  Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy?

Authors:  K M Boberg; F Brosstad; T Egeland; T Egge; E Schrumpf
Journal:  Thromb Haemost       Date:  1999-03       Impact factor: 5.249

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

7.  Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.

Authors:  Alenka Vizjak; Tomaz Rott; Mira Koselj-Kajtna; Blaz Rozman; Stasa Kaplan-Pavlovcic; Dusan Ferluga
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

8.  Distinguishing C1q nephropathy from lupus nephritis.

Authors:  Andrew Sharman; Peter Furness; John Feehally
Journal:  Nephrol Dial Transplant       Date:  2004-03-05       Impact factor: 5.992

9.  Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow-up of ANCA-associated vasculitis and Goodpasture's disease.

Authors:  J Damoiseaux; M Vaessen; Y Knapen; E Csernok; C A Stegeman; P Van Paassen; J W Cohen Tervaert
Journal:  Ann N Y Acad Sci       Date:  2007-08       Impact factor: 5.691

10.  ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis.

Authors:  Abraham Rutgers; Jan Damoiseaux; Caroline Roozendaal; Pieter C Limburg; Coen A Stegeman; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.